Login / Signup

Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis.

Amir HaddadNili SteinIdit LaviLisa ShynkarIrina BergmanIlan FeldhamerArnon Dov CohenWalid SalibaDevy Zisman
Published in: Biologics : targets & therapy (2023)
In this large observational retrospective cohort of patients treated with apremilast, a relatively low drug persistence was observed with 6-month and 1-year survival rates of 50.3% and 31.3%, respectively. Treatment discontinuation was mainly due to joint inefficacy, advocating for more studies for proper patient selection to assure treatment effectiveness and persistency.
Keyphrases
  • randomized controlled trial
  • systematic review
  • cross sectional
  • combination therapy
  • replacement therapy
  • free survival